

TDM	729.89	915.51	185.62	▲ 25.43%
HUM	749.73	924.29	174.56	▲ 23.28%
DMW	833.72	1004.01	170.29	▲ 20.43%
YZJ	903.49	1127.46	223.97	▲ 24.79%
GLY	982.07	1219.39	237.32	▲ 24.17%
VDA	113.74	143.41	29.67	▲ 26.09%
UVV	468.08	535.41	67.33	▲ 14.38%
HJS	545.49	659.05	113.56	▲ 22.22%

NordiQC data: Antibody selection, protocols and controls

The general module

PPJ	912.63	1038.36	125.73	▲ 13.78%
UAQ	1309.55	1655.62	346.07	▲ 26.43%
DAQ	1295.17	1641.66	345.49	▲ 26.75%
PNR	654.33	775.84	121.51	▲ 18.57%
ZTM	511.63	631.11	120.48	▲ 23.68%


Tanya Julio
Histotechnologist
Pathology department
Aarhus University Hospital,
DK

Primary panel for the unknown primary tumour




	CD45	Pan-CK	S100	Vimentin
Haematolymphoid neoplasms	+/-	-/(+)	-/(+)	+/-
Epithelial neoplasms	-	+/-	-/+	-/+
mesothelial neoplasms	-	+	-	+
mesenchymal and neuronal neoplasms	-	-/(+)	-/+	+
non-neuronal neuroepithelial neoplasms	-	-/(+)	+	+
Germ cell neoplasms	-	-/+	-/+	+

Participants



Pass-rate for the primary panel




Controls - Tonsil

HIER + 3-layer detectionsystem



RP2/18 Ventana RTU



No HIER + 2-layer detectionsystem


All lymphocytes (B- and T- cells) and histocytes must display a strong distinct membranous staining reaction. Squamous epithelial cells should be negative.

.... And Liver!

HIER + 3-layer detectionsystem




CD45, RP2/18 Ventana RTU




No HIER + 2-layer detectionsystem

The Kupffer cells should show a weak to moderate staining reaction whereas hepatocytes must be negative.

RUN 69-71 - Number of participants



Run 69-71 Score




CK8/18

1. Appendix, 2. Liver, 3. Tonsil, 4. Breast carcinoma, 5. Renal celle carcinoma



Optimal


Insufficient



Liver

Optimal


Insufficient



Renal celle Carcinoma


Optimal

Insufficient



Ductalt breast carcinoma

CK8/18



Ductal breast carcinoma

Table 1. Antibodies and assessment marks for CK8/18, Run 69

Concentrated antibodies	Reactivit y	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone B22.1/B23.1	<i>CK8/18</i>	16 2 1	Cell Marque Bio SB Immunologic	16	1	1	1	90%	84%
mAb clone 5D3	<i>CK8/18</i>	11 2 1 1 1	Leica Biosystems Biocare Diagnostic BioSystem Epredia Thermo Scientific	8	5	2	1	81%	50%
mAb clone CAM5.2	<i>CK8(7)</i>	2 2 2 1	BD Bioscience Becton Dickinson Zytomed Master Diagnostica	1	2	3	1	43%	14%
mAb clone DC10	<i>CK18</i>	6	Dako/Agilent	1	3	2	-	67%	17%
mAb clone ZM125	<i>CK8/18</i>	2	Zeta Corporation	-	-	2	-	-	-
mAb clone TS1	<i>CK8</i>	1	Thermo Scientific	1	-	-	-	-	-
mAb clone TS1+DC10 ("homebrew")	<i>CK8/18</i>	1	Thermo Scientific	-	1	-	-	-	-
rmAb clones EP17/EP30	<i>CK8/18</i>	14 2	Dako/Agilent Epitomics	15	1	-	-	100%	94%
rmAb clone EP17	<i>CK8</i>	4 3 1	Epitomics Cell Marque Bio SB	8	-	-	-	100%	100%
rmAb clone EP30	<i>CK18</i>	1	Cell Marque	1	-	-	-	-	-
rmAb+mAb clone IHC559	<i>CK8/18</i>	1	GenomeMe	1	-	-	-	-	-
rmAb clone QR112	<i>unknown</i>	1	Quartett	-	1	-	-	-	-

CK8/18

Run 69	No. of labs	Passrate	Development
CK8/18	282	85%, 65% optimale	↑

Table 2. Proportion of optimal results for CK8/18 for the most commonly used antibody as concentrate on the four main IHC systems*

Concentrated antibody	Dako/Agilent Autostainer	Dako/Agilent Omnis	Ventana/Roche BenchMark XT / Ultra	Leica Biosystems Bond III / Max / Prime					
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0 + P3	ER2 pH 9.0	ER1 pH 6.0	No Treatment
mAb clones B22.1/B23.1	1/1**	0/1	2/2	-	10/12 (83%)	-	2/2	-	1/1
mAb clone 5D3	1/3	-	½	-	-	0/1	4/5	-	0/3
mAb clone DC10	-	1/1	0/1	-	0/3	-	0/1	-	-
mAb clone CAM5.2	-	-	0/3	-	0/1	-	1/1	-	-
rmAb clones EP17/EP30	1/1	-	5/5 (100%)	-	3/4 (-	6/6 (100%)	-	-
rmAb clone EP17	1/1	-	-	-	7/7 (100%)	-	-	-	-

Table 3. Proportion of sufficient and optimal results for CK8/18 for the most commonly used RTU IHC systems


RTU systems	Recommended protocol settings*		Laboratory modified protocol settings**	
	Sufficient	Optimal	Sufficient	Optimal
Dako AS mAb DC10 IR618	-	-	0/3	0/3
Dako Omnis mAb DC10 GA618	0/3	0/3	25% (2/8)	13% (1/8)
Dako AS48 rmAb EP17/EP30 IR/IS094	100% (9/9)	78% (7/9)	100% (5/5)	60% (3/5)
Leica Bond mAb 5D3 PA0067	79% (11/14)	50% (7/14)	71% (5/7)	57% (4/7)
VMS Ultra/XT mAb B22.1/B23.1 760-4344	100% (20/20)	70% (14/20)	98% (59/60)	73% (44/60)
VMS Ultra/XT mAb CAM5.2 790-4555	-	-	4/4	3/4

B22.1/B23.1 VRPS: UltraView CC1 32 min, Ab 16 min

CAM5,2 VRPS: UltraView, P1 8 Min, Ab 16 min.

PSA

1. Prostate hyperplasia, 2. Appendix, 3. Colon adenocarcinoma, 4. Prostate adenocarcinoma, 5. Prostate adenocarcinoma.




Optimal




Insufficient




Optimal




Insufficient



Optimal



Insufficient



Prostata hyperplasi

Prostata Adenokarcinom

Prostata Adenokarcinom

PSA

Run 69	No. of labs	Passrate	Development
PSA	377	85%, 50% optimale	⬇️

Table 2. Proportion of optimal results for PSA for the most commonly used antibodies as concentrate on the four main IHC systems*

Concentrated antibody	Dako/Agilent Autostainer	Dako/Agilent Omnis	Ventana/Roche BenchMark GX/XT/Ultra	Leica Biosystems Bond III / Max
	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	ER2 pH 9.0
mAb clone ER-PR8	8/20** (40%)	0/1	20/35 (57%)	0/1
mAb clone 35H9	-	-	3/4	-
rmAb clone EP109	-	-	1/1	-
pAb 0562	0/1	0/1	4/6 (67%)	-
			7/18 (39%)	1/3
			13/16 (81%)	0/1
			0/2	6/11 (55%)
			8/16 (50%)	1/1
			-	0/2
				0/2

pAb 0562 from Agilent is terminated. Ventana users can use ER-PR8 or 35H9

Table 3. Proportion of sufficient and optimal results for PSA for the most commonly used RTU IHC systems


RTU systems	Recommended protocol settings*		Laboratory modified protocol settings**	
	Sufficient	Optimal	Sufficient	Optimal
VMS Ultra/XT/GX pAb 760-2506	100% (19/19)	53% (10/19)	93% (108/116)	60% (69/116)
VMS Ultra/XT/GX mAb ER-PR8 760-4271	-	-	67% (4/6)	33% (2/6)
BOND MAX/III mAb 35H9 PA0431	94% (15/16)	31% (5/16)	88% (15/17)	47% (8/17)

pAb: The protocol is available for both OptiView and ultraView.

ER-PR8: No one uses VRPS.

PSA

Prostate hyperplasia



Appendix

Table 4. Overview of the assessment marks for mAb clone ER-PR8 on the four main IHC instruments in run 69.

PSA score	Dako/Agilent Autostainer		Dako/Agilent Omnis		Ventana/Roche BenchMark GX / XT / Ultra		Leica Biosystems Bond III / Max
Detection system	2-layer	3-layer	2-layer	3-layer	2-layer	3-layer	3-layer
Optimal	5	3	10	10	-	7	1
Good	4	2	6	3	4	3	2
Borderline	5	-	8	-	-	3	2
Poor	2	-	-	-	-	1	-
Total	16	5	24	13	4	14	5
Sufficient %	56%	100%	67%	100%	100%	71%	60%

Prame



1. Compound nevus, 2. testis, 3-4 malignant melanoma





Table 1a. Overall results for PRAME, run 70

	n	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
Concentrated antibodies	108	40	32	28	8	67%	37%
Ready-To-Use antibodies	151	73	57	19	2	86%	48%
Total	259	113	89	47	10		
Proportion		44%	34%	18%	4%	78%	



Prame

Table 1c. Ready-To-Use antibodies and assessment marks for PRAME, run 70

Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
rmAb clone EPR20330 790-7149/7150 (VRPS)³	44	Ventana/Roche	25	18	1	0	98%	57%
rmAb clone EPR20330 790-7149/7150 (LMPS)⁴	58	Ventana/Roche	21	23	14	0	76%	36%
rmAb clone EPR20330 AVI/ALI/API3252	18	Biocare Medical	10	6	2	0	89%	56%
rmAb clone EPR20330 MAD-000793QD	5	Master Diagnostica	3	2	0	0	100%	60%
rmAb clone EPR20330 RMPD109	2	Diagnostic BioSystems	0	0	1	1	-	-
rmAb clone QR005 P-P003	11	Quartett	5	4	1	1	82%	45%
rmAb clone QR005 8355-C010	1	Sakura Finetek	1	0	0	0	-	-
rmAb clone EP461 484R-10/17/18	6	Cell Marque	5	1	0	0	100%	83%
rmab clone RBT-PRAME BSB-2374-3/7/15	3	Bio SB	1	2	0	0	-	-
rmAb clone E7I1B RMA-1047	2	Fuzhou Maixin Biotech	2	0	0	0	-	-
rmAb clone IHC092	1	GenomeMe	0	1	0	0	-	-
Total	151		73	57	19	2		
Proportion			48%	38%	13%	1%	86%	

OptiView 97/68%
 UltraView 100/33%
 UltraView AP 100/14%



Prame




Table 1b. Concentrated antibodies and assessment marks for PRAME, run 70

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
rmAb clone EPR20330	53	Abcam	18	18	14	3	68%	34%
rmAb clone EPR20330	15	Biocare Medical	8	2	4	1	67%	53%
rmAb clone EPR20330	10	Diagnostic BioSystems	5	4	1	0	90%	50%
rmAb clone EPR20330	1	Gennova	0	1	0	0	-	-
rmAb clone QR005	19	Quartett	2	7	8	2	47%	11%
rmAb clone EP461	7	Cell Marque	5	0	0	2	71%	71%
rmab clone RBT-PRAME	3	Bio SB	2	0	1	0	-	-
Total	108		40	32	28	8		
Proportion			37%	30%	26%	7%	67%	

*Same lot 171270


Table 2. Proportion of optimal results for PRAME for the most commonly used antibody as concentrate on the four main IHC systems*

Concentrated antibody	Dako/Agilent Autostainer ¹	Dako/Agilent Omnis	Ventana/Roche BenchMark ²	Leica Biosystems Bond ³
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	CC1 pH 8.5
rmAb clone EPR20330	3/9** (33%)	-	14/31 (45%)	8/24 (33%)
rmAb clone QR005	0/1	-	0/1	1/7 14%
rmAb clone EP461	-	-	0/1	3/3
				2/3



Testis


A moderate to strong nuclear staining reaction in most spermatogonia located at the basal part of seminiferous tubules while dispersed cells of early spermatogenesis should show a weak to moderate, distinct nuclear staining reaction.



Malignant melanoma

Virtually all tumor cells should display a weak to moderate nuclear staining reaction.

P53 - new purpose




International Journal of Gynecological Pathology
 38:S123–S131, Lippincott Williams & Wilkins, Baltimore
 Copyright © 2018 International Society of Gynecological Pathologists. Published by Wolters Kluwer Health, Inc.
 on behalf of the International Society of Gynecological Pathologists.

OPEN

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility

Martin Köbel, M.D., Brigitte M. Ronnett, M.D., Naveena Singh, M.D., Robert A. Soslow, M.D., C. Blake Gilks, M.D., and W. Glenn McCluggage, M.D.




E. High wild-type

F. Low wild-type

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility

Dako RTU
Flex+
protocol



Diluted RTU

Dako Flex
recommended
protocol

Diluted RTU

Table 4. Summarization of the proportion of sufficient and optimal marks using either 2- or 3-layer detection systems.**

Antibodies	n	2-layer detection system		3-layer detection system	
		Sufficient	Optimal	Sufficient	Optimal
mAb conc DO-7	90	25% (1/4)	0% (0/4)	74% (64/86)	41% (35/86)
mAb RTU BP53-11 760-2542* Ventana/Roche	50	15% (2/13)	0% (0/13)	65% (24/37)	19% (7/37)
mAb clone RTU DO-7 800-2912* Ventana/Roche	92	8% (1/12)	8% (1/12)	83% (66/80)	50% (40/80)
mAb clone RTU DO-7 IS/IR616* Dako/Agilent	32	30% (3/10)	10% (1/10)	77% (17/22)	50% (11/22)
mAb clone RTU DO-7 GA616* Dako/Agilent	72	16% (3/17)	0% (0/17)	84% (46/55)	16% (9/55)



20-50% of germinal centre B-cells must show a weak to moderate nuclear staining reaction, while 20-50% of the mantle zone B-cells should be demonstrated.

Concentrated antibodies	n	Vendor	Optimal				Good		Borderline		Poor		Suff. ¹		OR ²	
			Optimal	Good	Borderline	Poor	Suff. ¹	OR ²								
mAb clone DO-7	4	Cell Marque														
	56	Dako/Agilent														
	1	Diagnostic Biosystems														
	21	Leica Biosystems														
	1	Thermo Scientific														
Other	7						0	3	4	0	-	-				
Total	90						23	41	19	7						
Proportion							26%	46%	21%	7%	71%					
Ready-To-Use antibodies			n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²						
mAb clone BP53-11 760-2542 (VRPS)³	8	Ventana/Roche			0	3	2	3	38%	0%						
mAb clone BP53-11 760-2542 (LMPS)⁴	44	Ventana/Roche			6	25	6	7	70%	14%						
mAb clone DO-7 800-2912 (VRPS)³	8	Ventana/Roche			1	3	2	2	50%	13%						
mAb clone DO-7 800-2912 (LMPS)⁴	104	Ventana/Roche			20	55	26	3	72%	19%						
mAb clone DO-7 IS/IR616 (VRPS)³	5	Dako/Agilent			0	1	1	3	20%	0%						
mAb clone DO-7 IS/IR616 (LMPS)⁴	28	Dako/Agilent			4	15	5	4	68%	14%						
mAb clone DO-7 GA616 (VRPS)³	10	Dako/Agilent			0	3	0	7	30%	0%						
mAb clone DO-7 GA616 (LMPS)⁴	59	Dako/Agilent			7	39	7	6	78%	12%						
mAb clone DO-7 PA0057 (VRPS)³	19	Leica Biosystems			0	4	14	1	21%	0%						
mAb clone DO-7 PA0057 (LMPS)⁴	12	Leica Biosystems			0	3	9	0	25%	0%						
Other	9				1	2	3	3	-	-						
Total	306				39	153	75	39								
Proportion					13%	50%	24%	13%	63%							


PMS2

Table 1a. Overall results for PMS2, run 71


	n	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
Concentrated antibodies	56	29	14	8	5	77%	52%
Ready-To-Use antibodies	324	104	91	95	34	60%	32%
Total	380	133	105	103	39		
Proportion		35%	28%	27%	10%	63%	



1. Tonsil, 2. Appendix, 3. Colon
adenocarcinoma with normal PMS2, 4-5
Colon adenocarcinoma with loss of PMS2




Negative tumor





A

Negative tumor



B

GA087
RTU



790-5094
RTU

Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone A16-4 790-5094 (VRPS)³	50	Ventana/Roche OptiView+AMP , 760-700+760-099/860-099	2	14	24	10	32%	4%
mAb clone A16-4 790-5094 (LMPS)⁴	80	Ventana/Roche OptiView	6	13	45	16	24%	8%
rmAb clone EP51 GA087 (VRPS)³	45	Dako/Agilent	32	12	1	-	98%	71%
rmAb clone EP51 GA087 (LMPS)⁴	27	Dako/Agilent	16	8	3	-	89%	59%
rmAb clone EP51 PA0991 (VRPS)³	12	Leica Biosystems	4	8	-	-	100%	33%
rmAb clone EP51 PA0991 (LMPS)⁴	15	Leica Biosystems	3	8	4	-	73%	20%
Total	324		104	91	95	33		
Proportion			32%	28%	30%	10%	60%	

116 using amp,
97 labs had background

Cut out of table 1.c

Table 4. Antibodies and assessment marks for PMS2 strictly on the Ventana Benchmark platform.
Concentrates and prediluted Abs are pooled together.


RTU/conc	n	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone A16-4 790-5094 (VRPS) ³	50	2	14	24	10	32%	4%
mAb clone A16-4	85	6	14	49	16	24%	7%
rmAb clone EP51	46	26	9	5	6	76%	56%
rmAb clone EPR3947	11	5	1	5	-	55%	46%
Total	192	39	38	83	32	40%	

Run 53

mAb clone A16-4 790-5094	4	Ventana/Roche	2	2	0	0	-	-
rmAb clone EPR3947 760-4531	83	Ventana/Roche	45	28	9	1	88%	89%

Run 62


mAb clone A16-4 790-5094 (VRPS) ³	33	Ventana/Roche	5	11	17	0	49%	15%
mAb clone A16-4 790-5094 (LMPS) ⁴	86	Ventana/Roche	11	22	42	11	38%	13%



CK-PAN

Table 1a. Overall results for CK-PAN, run 71

	n	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
Concentrated antibodies	124	58	23	25	18	65%	47%
Ready-To-Use antibodies	286	147	59	44	36	72%	51%
Total	410	205	82	69	54		
Proportion		50%	20%	17%	13%	70%	





Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR ²
mAb clone cocktail AE1/AE3	4	Cell Marque	1	-	1	2		
	63	Dako/Agilent	37	11	8	7	76%	59%
	1	DCS Diagnostics	-	1	-	-		
	1	Diagnostic Biosystems	-	-	-	1		
	2	Epredia	-	1	1	-		
	1	GenomeMe	-	1	-	-		
	9	Leica Biosystems	-	1	5	3	11%	0%
	1	Zeta Corporation	-	-	-	1		
	3	Zytomed Systems	-	1	2	-		
mAb clone cocktail AE1/AE3/5D3	1	Abcam	-	-	1	-	-	-
	1	Biocare Medical	-	-	1	-	-	-
	4	Zytomed Systems	1	1	-	2	-	-
mAb clone cocktail PAN CK (Ab C2562)	1	Sigma Aldrich	1	-	-	-	-	-
mAb clone BS5	2	Monosan	1	1	-	-	-	-
	17	Nordic Biosite	13	4	-	-	100%	76%
mAb clone MNF116	6	Dako/Agilent	1	-	3	2	-	-
mAb clone OSCAR	1	Cell Marque	1	-	-	-	-	-
rmAb clone QR124	1	Quartett	1	-	-	-	-	-
Total	124		58	23	25	18		
Proportion			47%	18%	20%	14%	65%	

Table 2. Proportion of optimal results for CK-PAN for the most commonly used antibody concentrates on the four main IHC systems*


Concentrated antibodies	Dako/Agilent Autostainer¹		Dako/Agilent Omnis		Ventana/Roche BenchMark²		Leica Biosystems Bond³	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0	BERS2 pH 9.0	BERS1 pH 6.0
mAb clone AE1/AE3	3/1**	1/1	6/6 (100%)	0/1	26/46 (57%)	-	1/6 (17%)	0/1
mAb clone BS5	-	-	4/4	-	4/5 (80%)	-	4/8 (50%)	2/2

Table 1c. Ready-To-Use antibodies and assessment marks for CK-PAN, run 71

Ready-To-Use antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff. ¹	OR. ²
mAb clone cocktail AE1/AE3/PCK26 760-2135/2595 (VRPS)³	25	Ventana/Roche	5	17	2	1	88%	20%
mAb clone cocktail AE1/AE3/PCK26 760-2135/2595 (LMPS)⁴	114	Ventana/Roche	52	21	22	19	64%	46%
mAb clone cocktail AE1/AE3 IR/IS053 (VRPS)³	12	Dako/Agilent	10	2	-	-	100%	83%
mAb clone cocktail AE1/AE3 IR/IS053 (LMPS)⁴	15	Dako/Agilent	5	4	4	2	60%	33%

Table 4. Pass rates for antibody cocktails combined with epitope retrieval methods in the last three NordiQC runs

mAb clone cock GA053 (LMPS)	Pass rate for compiled data from run 54, 58 and 71								
	Total		HIER		Proteolysis		HIER + proteolysis		
	Protocols	Sufficient	Protocols	Sufficient	Protocols	Sufficient	Protocols	Sufficient	
mAb AE1/AE3	609	449 (74%)	579	442 (76%)	12	1 (8%)	9	1 (11%)	
mAb AE1/AE3/5D3	21	12 (57%)	21	12 (57%)	-	-	-	-	
mAb AE1/AE3/PCK26	323	208 (64%)	39	22 (56%)	28	3 (11%)	254	181 (71%)	
mAb MNF116	27	2 (7%)	18	0 (0%)	7	2 (29%)	1	0	
mAb BS5	38	36 (95%)	38	36 (95%)	-	-	-	-	




HIER+P3
OptiView

© NordiQC	mAb clone cocktail AE1/AE3/PCK26 760-2135/2595 (VRPS)³	25	Ventana/Roche	11	8	4	2	76%	44%
	mAb clone cocktail AE1/AE3/PCK26 760-2135/2595 (LMPS)⁴	69	Ventana/Roche	29	19	10	11	70%	42%

HIER
OptiView

Photos of Clear cell renal
cell carcinoma




P1
OptiView

CD117

Table 1a. Overall results for CD117, run 71

	n	Optimal	Good	Borderline	Poor	Suff. ¹	OR. ²
Concentrated antibodies	240	152	70	15	3	93%	63%
Ready-To-Use antibodies	188	152	28	7	1	96%	81%
Total	428	304	98	22	4		
Proportion		71%	23%	5%	1%	94%	

CD117 performance in NordiQC assessments



KEY POINTS FOR CD117 IMMUNOASSAYS

- The rmAb clones **EP10** and **YR145** are recommendable Abs.
- The pAb **A4502** performed superiorly compared to the previous NordiQC CD117 assessment runs, however the proportion of optimal results was inferior to rmAbs EP10 and YR145.
- The new Ventana/Roche RTU system **790-7061** based on rmAb clone EP10 performed superiorly compared to the previous Ventana/Roche RTU system based on rmAb clone 9.7.
- RTU systems, especially the Leica Biosystems RTU system **PA0007**, were successful.
- The TMA circulated only consisted of solid tissues with moderate to high expression levels of CD117 and no data was generated on performance of the protocols assessed in other relevant materials as e.g. bone marrow.

Appendix - Cajal cells are critical, and muscle should be negative



Appendix - Mast cells are strongly positive.

